Research programme: metabolic disorders therapy - OPiAlternative Names: Metabolic disorders therapy research programme - OPi; OPM005
Latest Information Update: 19 Feb 2008
At a glance
- Originator OPi
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 17 May 2005 Preclinical trials in Metabolic disorders in France (unspecified route)